IP Library › Granted Patent US 9,732,367
Granted Patent B2
US 9,732,367 · App. 14/430,542 · Granted Aug 15, 2017

Cell lines

Inventors: Kenneth H. Grabstein (Mercer Island, WA); Michael Van Brunt (Covington, WA); Marcello Marelli (Seattle, WA); William Brady (San Diego, CA); Jeffrey C. Johnson (Flemington, NJ)
Assignee: MEDIMMUNE LIMITED
C12P21/02A61K47/48569C07C233/49C07C233/56C07C235/74C07C247/04C07C271/12C07C271/20C07C271/22C07K14/43595C07K16/244C07K16/248C07K16/2863C07K16/32C07K16/40C07K16/46C07K17/08C12N9/93C12N15/85C07K2317/14C07K2317/24C07K2317/31C07K2317/40C07K2317/51C12Y601/01025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,732,367
App. No.
14/430,542
Filed
Mar 23, 2015
Granted
Aug 15, 2017
Kind
B2
Art Unit
1636
USPC
435/69.1
Abstract

There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.

Claims (16)

1. A process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl, wherein the cell line is capable of incorporating a gene encoding a target protein and wherein said target protein comprises one or more non-natural amino acids encoded by an amber codon, wherein said process comprises culturing said cell line in the presence of a decoy amino acid of:

(a) formula VIIA:

wherein K is CO or SO 2 ;

Q=H, C 1-6 alkyl, aryl, heteroaryl, -OC 1-6 alkyl, -OCH 2 aryl, -OCH 2 heteroaryl, C 2-6 alkenyl or -OC 2-6 alkenyl; or

(b) formula VIIB:

wherein G=H;

a=4 or 5; and

R=C 1-6 alkyl, C 2-6 alkenyl, CH 2 aryl, C 2-6 alkynyl, C 1-6 haloalkyl or C 1-6 azidoalkyl,

wherein the viability of said eukaryotic cell line is enhanced in comparison to the viability of said eukaryotic cell line cultured in the absence of said decoy amino acid.

2. A process according to claim 1 wherein the decoy amino acid is selected from:

3. A process according to claim 1 wherein the expression of tRNAPyl occurs under the control of a repressible promoter.

4. A process according to claim 1 wherein the eukaryotic cell line is a mammalian cell line is selected from CHO, HEK293, PERC6, COS-1, COS-7, HeLa, VERO, mouse hybridoma and mouse myeloma cell lines.

5. A process according to claim 1 wherein the nonsense codon is an amber codon.

6. A process according to claim 1 wherein the compound of formula VII is a compound of formula VIIA:

wherein K is CO or SO2;

Q=—H, C1-6alkyl, aryl, heteroaryl OC1-6alkyl, —OCH2aryl, —OCH2heteroaryl, —C2-6alkenyl or —OC2-6alkenyl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2015
From: GRABSTEIN, KENNETH H.; VAN BRUNT, MICHAEL; MARELLI, MARCELLO; BRADY, WILLIAM; JOHNSON, JEFFREY
To: ALLOZYNE, INC.
Reel/Frame 036179/0355 →
Continuity (3)
Provisional Application 61862495 · Aug 5, 2013
Provisional Application 61705116 · Sep 24, 2012
Related Publication 20150259721A1 · Sep 17, 2015